Press release
Atopic Dermatitis Pipeline Outlook Report 2024
Key Takeaways from the Atopic Dermatitis Pipeline Report
* August 2024:- Amgen- A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO).
* August 2024:- Eli Lilly and Company- This study will also include an Addendum to extend the study treatment period by an additional 32 weeks and to add a treatment arm testing dosing every 8 weeks. This Addendum will apply to existing study participants in selected countries. Treatment will not be blinded.
* DelveInsight's Atopic Dermatitis pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Atopic Dermatitis treatment.
* The leading companies working in the Atopic Dermatitis Market include Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others.
* Promising Atopic Dermatitis Pipeline Therapies in the various stages of development include Baricitinib, Topical corticosteroid, si-544, Lebrikizumab, MEDI9929, and others.
Request a sample and discover the recent advances in Atopic Dermatitis Treatment Drugs @ Atopic Dermatitis Pipeline Report [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
In the Atopic Dermatitis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atopic Dermatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Atopic Dermatitis Overview
Atopic dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word 'dermatitis,' 'derm' means 'skin' and 'itis' means 'inflammation.' Thus, dermatitis is a skin inflammation characterized by itchiness, redness and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances.
Find out more about Atopic Dermatitis Therapeutics Assessment @ Atopic Dermatitis Preclinical and Discovery Stage Products [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Atopic Dermatitis Emerging Drugs Profile
* Tapinarof: Dermavant Sciences
* Etrasimod: Pfizer
* B244: AOBiome
* Lirentelimab: Allakos Inc.
* QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Atopic Dermatitis Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the Atopic Dermatitis therapies. The Atopic Dermatitis companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. phase III include, Dermavant Sciences.
DelveInsight's Atopic Dermatitis pipeline report covers around 110+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Atopic Dermatitis Pipeline Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Learn more about the emerging Atopic Dermatitis Pipeline Therapies @ Atopic Dermatitis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Atopic Dermatitis Pipeline Report
* Coverage- Global
* Atopic Dermatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Atopic Dermatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Atopic Dermatitis Companies- Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others.
* Atopic Dermatitis Pipeline Therapies- Baricitinib, Topical corticosteroid, si-544, Lebrikizumab, MEDI9929, and others.
Dive deep into rich insights for new drugs for Atopic Dermatitis Treatment, Visit @ Atopic Dermatitis Market Drivers and Barriers, and Future Perspective [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Atopic Dermatitis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Atopic Dermatitis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Tapinarof: Dermavant Sciences
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* B244: AOBiome
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* EP262: Escient Pharmaceuticals
* Drug profiles in the detailed report.....
* Inactive Products
* Atopic Dermatitis Key Companies
* Atopic Dermatitis Key Products
* Atopic Dermatitis- Unmet Needs
* Atopic Dermatitis- Market Drivers and Barriers
* Atopic Dermatitis- Future Perspectives and Conclusion
* Atopic Dermatitis Analyst Views
* Atopic Dermatitis Key Companies
* Appendix
For further information on the Atopic Dermatitis Pipeline therapeutics, reach out to Atopic Dermatitis Unmet Needs and Analyst Views [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=atopic-dermatitis-pipeline-outlook-report-2024]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atopic Dermatitis Pipeline Outlook Report 2024 here
News-ID: 3612948 • Views: …
More Releases from ABNewswire
The Reverend Dr. Anthony Hodge: Championing Personal Transformation Through Fait …
South Carolina - The Reverend Dr. Anthony Hodge, retired U.S. Navy Chaplain, certified Spiritual Director, and Christian Counselor, is making waves in the world of Christian living with his empowering message: it is never too late to transform your life.
As the author of two inspirational books - Can You Get Better? Sure You Can!: 14 Approaches Guaranteed to Help You Become a Better You and A Better You: Christian Life…
Fitness Industry Veteran Launches Dino Labz Online Store with Three-Tier Product …
Tampa-based Dino Labz LLC introduces curated fitness store through founder's extensive expertise including NASM certification, American Ninja Warrior competition, and bodybuilding preparation. The company's three-tier product collections help athletes find the right products for their training level.
Tampa-based Dino Labz LLC launches a revolutionary online fitness store, founded by an industry veteran whose comprehensive expertise spans professional personal training, elite athletic competition, and competitive bodybuilding preparation. Opening September 1st, 2025, with…
Business Address, Zero Rent: How TEC Virtual Office Helps Startups Gain Professi …
Image: https://www.abnewswire.com/upload/2025/09/e3c32aa3425ad3e972329b803ae47d7b.jpg
Small firms and start-ups often run from spare rooms, cafes, or small shared spaces. Yet your address still shapes how people see your business. In Singapore and other busy markets, you can't afford to look small or unsure.
This blog explains how a virtual office gives you a strong address, privacy, and a smarter way to run your brand. You will learn about the value of a business address, extra…
Concord Marine Electronics Completes 170 Yacht Builder Projects with Advanced St …
Concord Marine Electronics, Inc., a 35-year marine technology leader, announces milestone achievements including over 300 Starlink Performance Kit installations and completion of 170 yacht builder program projects. The company specializes in comprehensive marine electronics, audio-video systems, and high-speed internet solutions for vessels ranging from 30ft to 300ft.
Concord Marine Electronics, Inc. has reached significant milestones in the luxury marine technology sector, establishing itself as the premier one-stop solution for comprehensive marine…
More Releases for Atopic
Atopic Dermatitis Market Trends That Will Shape the Next Decade: Insights from P …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
How Large Will the Atopic Dermatitis Market Size By 2025?
The market size for atopic dermatitis has seen significant expansion in the past few years. This expansion is anticipated to continue, with the market size increasing from $8.61 billion in 2024 to $9.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of…
Advanced Therapy Revolutionizes Atopic Dermatitis Market Prospects
The atopic dermatitis market size is expected to be valued at USD 15.42 Billion in 2024 and reach USD 30.5 Billion by 2029, growing at a CAGR of 14.5 % from 2024 to 2029.
Atopic dermatitis, known as eczema, is a prevalent skin condition marked by red, inflamed, and itchy skin. It is a chronic condition commonly seen in children but can also impact adults. Atopic dermatitis is thought to result…
Atopic Dermatitis - Drug Pipeline Landscape, 2023
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may crak and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness. Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger…
Atopic Dermatitis - Drug Pipeline Landscape, 2022
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may cr*ck and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an…
Atopic Dermatitis (Atopic Eczema) Treatment Market Business Growth And Industry …
Precision Business Insights published a research report on “Atopic Dermatitis (Atopic Eczema) Treatment Market by Drug type (Corticosteroids, Calcineurin Inhibitors, Immunosuppressants, Phosphodiesterase type 4 (PDE-4) Inhibitors, Antibiotics, Antihistamines, Emollients), Route of administration (Oral, Topical, Parenteral), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography - Global/Region/Country Forecast to 2027”.
In people who suffer from atopic dermatitis, allergies play a big influence. When the patient is exposed to…
Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H2 2018 - ResearchByMarkets …
"Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H2 2018", provides an overview of the Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline landscape.
Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from…
